🏛️ Verified NIH Record • Updated 2026-07-16
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer (NCT05425940)
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Exelixis
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Who can join: Review the eligibility criteria below.
Location: Exelixis Clinical Site #65 — Jonesboro, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (133 Sites)
Showing the first 25 of 133 sites.
- Exelixis Clinical Site #65 — Jonesboro, Alabama
- Exelixis Clinical Site #30 — Phoenix, Arizona
- Exelixis Clinical Site #70 — Tucson, Arizona
- Exelixis Clinical Site #9 — Duarte, California
- Exelixis Clinical Site #55 — La Jolla, California
- Exelixis Clinical Site #77 — Los Angeles, California
- Exelixis Clinical Site #105 — Orange, California
- Exelixis Clinical Site #80 — Santa Monica, California
- Exelixis Clinical Site #5 — Santa Rosa, California
- Exelixis Clinical Site #82 — Sylmar, California
- Exelixis Clinical Site #58 — Torrance, California
- Exelixis Clinical Site #81 — Whittier, California
- Exelixis Clinical Site #125 — New Haven, Connecticut
- Exelixis Clinical Site #16 — Miami Beach, Florida
- Exelixis Clinical Site #60 — Orlando, Florida
- Exelixis Clinical Site #4 — Marietta, Georgia
- Exelixis Clinical Site #3 — Joliet, Illinois
- Exelixis Clinical Site #102 — Indianapolis, Indiana
- Exelixis Clinical Site #10 — Westwood, Kansas
- Exelixis Clinical Site #47 — Lexington, Kentucky
- Exelixis Clinical Site #7 — New Orleans, Louisiana
- Exelixis Clinical Site #22 — St Louis, Missouri
- Exelixis Clinical Site #8 — Billings, Montana
- Exelixis Clinical Site #1 — Omaha, Nebraska
- Exelixis Clinical Site #15 — Albuquerque, New Mexico
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer
- Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes — Los Angeles, California
- A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Duarte, California
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) — Houston, Texas
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver — Basking Ridge, New Jersey
- The PRIME-CRC Trial to Promote CRC Screening in Rural Communities — Bastrop, Louisiana
- Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer — Concord, California
Explore by condition: All Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.